Literature DB >> 8732743

Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin.

S A Dobie1, A J Ellsworth, M L Linenberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8732743      PMCID： PMC1303519     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  22 in total

Review 1.  Heparin.

Authors:  J Hirsh
Journal:  N Engl J Med       Date:  1991-05-30       Impact factor: 91.245

Review 2.  Use of anticoagulants during pregnancy.

Authors:  J S Ginsberg; J Hirsh
Journal:  Chest       Date:  1989-02       Impact factor: 9.410

Review 3.  Low molecular weight heparin.

Authors:  J Hirsh; M N Levine
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

4.  Hemorrhagic complications of anticoagulant therapy.

Authors:  M N Levine; J Hirsh
Journal:  Semin Thromb Hemost       Date:  1986-01       Impact factor: 4.180

5.  Heparin effect on bone density.

Authors:  J S Ginsberg; G Kowalchuk; J Hirsh; P Brill-Edwards; R Burrows; G Coates; C Webber
Journal:  Thromb Haemost       Date:  1990-10-22       Impact factor: 5.249

6.  Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.

Authors:  C I Lagerstedt; C G Olsson; B O Fagher; B W Oqvist; U Albrechtsson
Journal:  Lancet       Date:  1985-09-07       Impact factor: 79.321

7.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; G F Pineo; D Green; A A Trowbridge; C G Elliott; R G Lerner; J Hall; T Sparling; H R Brettell
Journal:  N Engl J Med       Date:  1992-04-09       Impact factor: 91.245

8.  Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis.

Authors:  M T Nurmohamed; F R Rosendaal; H R Büller; E Dekker; D W Hommes; J P Vandenbroucke; E Briët
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

9.  Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.

Authors:  G Rostoker; I Durand-Zaleski; M Petit-Phar; A Ben Maadi; N Jazaerli; C Radier; A Rahmouni; D Mathieu; N Vasile; J Rosso
Journal:  Nephron       Date:  1995       Impact factor: 2.847

10.  Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.

Authors:  R Hull; T Delmore; E Genton; J Hirsh; M Gent; D Sackett; D McLoughlin; P Armstrong
Journal:  N Engl J Med       Date:  1979-10-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.